Immunome, Inc.
↗Bothell, Washington, USA
Immunome is a clinical-stage biotechnology company focused on the discovery, design, development, and commercialization of targeted oncology therapeutics. The company specializes in antibody-drug conjugates (ADCs) and other innovative cancer therapies, leveraging a leadership team with extensive experience in developing and commercializing successful oncology treatments.
Following a merger with MorphImmune in October 2023, the company has accelerated its clinical pipeline. Its lead asset, varegacestat (a gamma secretase inhibitor), has shown positive results in Phase 3 trials for desmoid tumors, with an NDA submission planned for 2026. The company also maintains a robust preclinical and early-clinical pipeline of ADC candidates for various solid tumors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$5M-$10M
Founded:2006
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:$54.2M (pre-IPO/VC)
Investors:Enavate Sciences, EcoR1 Capital, Redmile Group, Janus Henderson Group, Avidity Partners, Woodline Partners
STOCK
Exchange:NASDAQ
Ticker:IMNM
Market Cap:$2.68B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (Varegacestat)
Modalities:Small molecule, ADC, Radioligand therapy
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AbbVie (collaboration on discovery engine)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Moderna, Advanced Accelerator Applications
LEADERSHIP
Key Executives:
Clay B. Siegall - President & CEO
Max Rosett - CFO
Roee Shahar - EVP, Commercial
Scientific Founders:Scott Dessain
Board Members:Clay Siegall, Jean-Jacques Bienaimé, Isaac Barchas, Sandra M. Swain
LINKS
Website:immunome.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Immunome, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Immunome, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.